- Fee assured
- Verified this account
This healthcare professional let us know that they are currently:
- Accepting new patients
- Available for:
- Face-to-face consultations
- Phone consultations
- Video consultations
Last updated: 29 Jun 2020
- Home chemotherapy
Mike Dennis is a Clinical Haematologist who is an established national expert in myeloid disease.
His expertise is in the management of acute myeloid leukaemia (AML), myelodysplasia (MDS), chronic myeloid leukaemia (CML), other associated myeloproliferative disorders (Myelofibrosis, CMML, ET, PRV) and bone marrow failure syndromes (including aplastic anaemia). This includes diagnosis and therapy (including stem cell transplantation)
He is a committee member of the NCRN working groups for AML and myelodysplasia, where his research roles include Chief investigator (Li1) and Co-chief investigator (AML 19) of the UK's premier front line AML studies.
His research focus is about getting access for patients to the most effective emerging agents. This is through clinical trial development of optimal therapy in AML of traditional and emerging agents, from site development and delivery of phase 1 studies to international trial governance and oversight.
He was appointed as a Consultant Haematologist at The Christie, Manchester in 2004. He qualified in Medicine from the University of Dundee, completed his physician’s training in Liverpool before undertaking his first Haematology post in Australia. He then completed his Haematology training, including a MD, from the University of Liverpool.
Areas of interest
• Leukaemias (AML and CML)
• Myelodysplastic syndrome (MDS)
• Myeloproliferative disorders (Myelofibrosis, ET, PRV, CMML)
• Aplastic aneamia
• Bone marrow transplantation
Current NHS consultant posts held
AML and myelodysplasia clinical trials.
Facilitating patient access to emerging therapies in AML.
Understanding the biology of leukaemia to inform new drug development.
Family life- wife is also a Dr and we have two teenagers and a dog.
Enjoy skiing, snowboarding and mountain biking to cope with the challenges of middle age.
Hope one day to see Man United win the league again.
Lead author research
Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear O, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden J, Dennis M. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
Biology of Blood and Marrow Transplantation (2016) 22:385-390.
Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Journal of Clinical Oncology (2019)
Russell N, Burnett A, Hills R, Betteridge S, Dennis M, Jovanovic J, Dillon R, Grimwade D; NCRI AML Working Group. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
Blood (2018) 132:1452-1454.
Bader P, Kuçi Z, Bakhtiar S, Basu O, Bug G, Dennis M, Greil J, Barta A, Kállay KM, Lang P, Lucchini G, Pol R, Schulz A, Sykora KW, von Luettichau I, Herter-Sprie G, Uddin MA, Jenkin P, Alsultan A, Buechner J, Stein J, Kelemen A, Jarisch A, Soerensen J, Salzmann-Manrique E, Hutter M, Schäfer R, Seifried E, Klingebiel T, Bonig H, Kuçi S. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).
Bone Marrow Transplantation (2018) 53:852-862.
Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P. Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
Clinical Cancer Research (2017) 23:6430-6440.
Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Leukemia (2017) 31:310-317.
- MB ChB University of Dundee 1991
- MRCP Royal College of Physicians, Edinburgh 1996
- FRCPath Royal College of Pathologists, London 2003
- MD University of Liverpool 2003
Reference number 3542754
Affiliations / memberships
American Society of Hematology, British Society for Haematology, the Royal College of Physicians, the Royal College of Pathologists and the European group for Blood and Marrow Transplantation (EBMT). A national committee member of both the AML and myelodysplasia (MDS) working groups of the National Cancer Research Network (NCRN)
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.